Clinical trials: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Condition Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Funder type Industry (pharma, biotech, devices)
Hematologic Neoplasms
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms.
- Trial name
- NCT00623870
- Testing
- RO5045337
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Chronic Myelogenous Leukemia - Chronic Phase
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.
- Trial name
- NCT04925141
- Testing
- Dasatinib Tablets
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Leukemia
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.
- Trial name
- NCT00006053
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated…
- Trial name
- NCT01456676
- Testing
- Nilotinib + LDE225
- Where
- 7 sites in Canada, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib
- Trial name
- MACS0254 (NCT00644878)
- Testing
- Nilotinib
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase…
- Conditions
- CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
- Trial name
- NCT03578367
- Testing
- Asciminib add-on, Imatinib, Nilotinib
- Where
- 30 sites in United States, Austria and 13 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Hematologic Malignancies, Leukemia
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Primary objective: To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of TCN-PM (Triciribine) when administered as an approximately one-hour intravenous infusion on a weekly schedule on days 1, 8 and…
- Trial name
- NCT00642031
- Testing
- Triciribine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prescient Therapeutics, Ltd.
Leukemia, Leukemia, Myeloid
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib)…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome
- Trial name
- NCT01602952
- Testing
- Radotinib
- Where
- 12 sites in India, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic…
- Trial name
- NCT02081378
- Testing
- Asciminib (ABL001), Nilotinib, Imatinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Hematologic Malignancies
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory…
- Trial name
- NCT00660920
- Testing
- Ponatinib
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Ariad Pharmaceuticals